TG Therapeutics reported second quarter 2026 total revenue of $240.3 million, up from $141.1 million a year earlier, and raised its full-year 2026 total global revenue target to approximately $950 million. Net income fell to $7.8 million from $28.2 million as research and development and selling, general and administrative expenses rose sharply, so higher sales did not translate into higher profit.
Q2 2026 total revenue was $240.3 million, versus $141.1 million in Q2 2025; BRIUMVI U.S. net product revenue was $227.7 million.
Q2 2026 net income was $7.8 million ($0.05 diluted per share), versus $28.2 million ($0.17 diluted per share) in Q2 2025.
Q2 2026 R&D expense was $95.3 million and SG&A expense was $82.1 million, versus $31.8 million and $55.6 million a year earlier.
Full-year 2026 targets were raised: total global revenue to approximately $950 million and BRIUMVI U.S. net product revenue to approximately $890 to $905 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From TG Therapeutics, Inc.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$616.29M
+87.3%
$2.77
+1746.7%
72.6%
FY2024
$329.00M
+40.8%
$0.15
+66.7%
7.1%
FY2023
$233.66M
+8290.0%
$0.09
—
5.4%
FY2022
$2.79M
-58.4%
$-1.65
—
-8036.3%
FY2021
$6.69M
+4300.7%
$-2.63
—
-5204.1%
Frequently asked questions
When is TG Therapeutics's next earnings date?
TG Therapeutics (TGTX) is scheduled to report on Monday, November 09, 2026 before the market opens. Analysts expect EPS of $0.37.
What did TG Therapeutics earn last quarter?
For the quarter ended Jun 2026, TG Therapeutics reported diluted EPS of $0.05 (-70.6% year over year) on revenue of $240.34M (+70.3%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.